PERIPHERAL T CELL LYMPHOMA

This early-phase trial tests a genetically modified virus (VSV-hIFNβ-NIS) combined with an immunotherapy drug (cemiplimab) in adults with relapsed or refractory T-cell lymphoma. The virus is designed to kill cancer cells while leaving healthy cells alone, and the immunotherapy he…

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and myeloma that have not responded to standard treatments. The drug is given as an oral capsule, either alone or combined with other cancer medicines. The goal i…

This early-stage trial tests a new gene therapy for certain T-cell lymphomas that have come back or not responded to treatment. The therapy uses a patient's own white blood cells, modified to attack cancer cells that carry a protein called CCR4. Up to 60 adults will receive the m…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This early-phase study tests a new approach for patients with certain lymphomas (Hodgkin, NK/T-cell, and others) that have returned or not responded to treatment. The therapy uses immune cells from healthy donors that are specially trained in the lab to attack cancer cells carryi…

This early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…

This Phase 3 trial tests a new drug, golidocitinib, against standard treatments for adults with relapsed or refractory peripheral T-cell lymphoma, a rare blood cancer. About 218 participants worldwide will receive either golidocitinib pills or a doctor-chosen drug. The goal is to…

This phase 3 trial compares two drug combinations given after a stem cell transplant to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The study will enroll 572 adults with blood cancers like leukemia or myelodysplasi…

This study tests a combination of two drugs, GW5282 and golidocitinib, for people with T-cell lymphoma. The first part finds the safest dose; the second part compares the combo to standard chemotherapy. About 165 adults with newly diagnosed or relapsed disease will take part. The…

This phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…

This early-phase trial tests a new approach for people with certain lymphomas that have come back or not responded to treatment. Researchers take immune cells from healthy donors, modify them to recognize and attack CD30-positive cancer cells, and add a molecule (C7R) to boost th…

This study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Pa…

This study tests whether combining two drugs—sintilimab and chidamide—can help people with a rare type of lymphoma (peripheral T-cell lymphoma) that has returned or not responded to prior treatments. About 51 adults aged 18 to 75 will receive the drug combination. The goal is to …

This study is for people with peripheral T-cell lymphoma whose cancer did not shrink or got worse after standard first treatment. It compares a stem cell transplant from a donor to other rescue treatments. The goal is to see which approach helps people live longer and control the…

This program offers early access to the investigational drug selinexor for people with certain advanced cancers, such as multiple myeloma, lymphoma, sarcoma, and others, who have no other treatment options. Patients must not qualify for any ongoing clinical trial and must have ex…

This Phase 3 trial tests whether the drug golidocitinib can help people with peripheral T-cell lymphoma (PTCL) stay in remission longer after their first round of chemotherapy. About 136 patients who responded to chemo will receive either golidocitinib or a placebo pill every oth…

This phase 2 trial is testing whether adding the targeted drug golidocitinib to standard chemotherapy (CHOP) can better control newly diagnosed peripheral T cell lymphoma, a rare and aggressive blood cancer. About 30 adults will receive the combination, and researchers will monit…

This study tests whether combining two drugs, cidabenamine and azacitidine, can stop high-risk peripheral T-cell lymphoma from progressing after a stem cell transplant. About 40 adults aged 18 to 70 will receive the drug combo as maintenance therapy. The goal is to see if it impr…

This study tests an experimental drug called HH2853 in people with certain types of blood cancer (non-Hodgkin lymphoma) or advanced solid tumors that have come back or stopped responding to treatment. The drug is taken as a tablet twice a day. The main goals are to find the safes…

This study looks at whether a stem cell transplant (using a patient's own cells) after successful first treatment can help control peripheral T-cell lymphoma. About 160 people will either get the transplant or just be monitored. The goal is to see if the transplant delays the can…

This study tests whether combining the drug golidocitinib with either mitoxantrone liposome or chidamide can safely shrink tumors in people with peripheral T-cell lymphoma that has returned or not responded to prior therapy. About 101 adults will receive one of the combinations. …

This study compares two types of stem cell transplants for people with peripheral T-cell lymphoma whose cancer only partially responded to first treatment. One group receives their own stem cells, the other receives cells from a matched donor. The goal is to see which approach le…

This phase II trial is testing whether adding the JAK inhibitor ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with relapsed or refractory Hodgkin and non-Hodgkin lymphomas. The study will enroll 53 participants with specific lymphoma subtype…

This study tests a new combination of two targeted drugs (linperlisib and chidamide) against standard chemotherapy for people with a rare type of blood cancer called peripheral T-cell lymphoma. The goal is to see if the new combo works better at shrinking tumors and controlling t…

This phase 3 trial tests whether adding either belinostat or pralatrexate to standard chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatme…

This Phase 2 trial tests a combination of the drug linperlisib plus three older drugs (cyclophosphamide, prednisone, and thalidomide) in 180 adults with non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to see how many patients achieve a complete o…

This study tests a new approach for people with peripheral T-cell lymphoma that has come back or not responded to standard treatments. Researchers take a patient's own immune T-cells, modify them in the lab to recognize and attack cancer cells carrying the CD30 protein, and infus…

This early-stage trial is testing a new form of fenretinide (a vitamin A-like drug) given by IV for people with T-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The study has two parts: first, finding the safest dose in small groups of patients, …

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…

This study will follow 3000 people in China with peripheral T-cell lymphoma, a rare and aggressive blood cancer. Researchers will track which treatments patients actually receive and how they fare, aiming to build better prediction tools and understand why some patients relapse. …